Evaluation of the Use of Intraoperative Subconjunctival Injection of Triamcinolone Acetonide and Limited Peritomy during Bare Scleral Pterygium Excision

Main Article Content

Alaa M. Abdelhafez
Samir Yehia Saleh
Abdelsalam Abdalla Mohamed
Ahmed F. Omar

Abstract

Aims: To evaluate the efficacy and safety of subconjunctival injection of triamcinolone acetonide (TA) and limited peritomy during bare scleral pterygium excision in preventing pterygium recurrence.

Study Design: A prospective non-randomized interventional case series.

Place and Duration of Study: All surgeries were done at the department of ophthalmology of Assiut university hospital (27 eyes) and Alforsan eye center in Assiut (3 eyes), Egypt, between November 2017 to December 2019.

Methodology: Thirty eyes of 26 patients who underwent pterygium excision with bare sclera combined with intraoperative subconjunctival TA injection and limited peritomy primary pterygium grade 2 (T2, 3 eyes) and grade 3 (T3, 30 eyes). All patients were followed up for 12 months after surgery. Pterygium recurrence and complications were the key outcome steps.

Results: Pterygium recurrence was seen in 3 eyes (10.0%) as following: grade 2 in one eye (3.3%) and grade 3 in two eyes (6.7%). Intraocular pressure elevation was observed in 9 eyes (30%). The IOP rise ranged from (22.4 to 37 mmHg). All eyes were successfully treated medically and reached normal values by the end of postoperative sixth month.

Conclusion: This procedure appears to be reasonably safe and successful in reducing pterygium recurrence.

Keywords:
Pterygium, recurrence, triamcinolone acetonide, intraocular pressure.

Article Details

How to Cite
Abdelhafez, A. M., Saleh, S. Y., Mohamed, A. A., & Omar, A. F. (2021). Evaluation of the Use of Intraoperative Subconjunctival Injection of Triamcinolone Acetonide and Limited Peritomy during Bare Scleral Pterygium Excision. Ophthalmology Research: An International Journal, 14(1), 30-39. https://doi.org/10.9734/or/2021/v14i130182
Section
Original Research Article

References

1. Sudhalkar A. Fixation and its role in the causation, laterality and location of pterygium: A study in amblyopes and non-amblyopes. Eye Net. 2012;26(3):438.
DOI:https://doi.org/10.1038/eye.2011.322. PMid:22157914. PMCid:PMC3298993.
2. Rogosnitzky M. Methods of eye treatment using therapeutic compositions containing dipyridamole. Google Patents; 2019.
3. Kim KW, Kim JC. Current approaches and future directions in the management of pterygium. International journal of ophthalmology. 2018;11(5):709.
4. Nassar MK, El-Sebaey A-R, Abdel-Rahman MH, El-Ghonemy K, Shebl AM. Clinical, pathological and molecular aspects of recurrent versus primary pterygium. Menoufia Medical Journal. 2014;27(2):386.
DOI:https://doi.org/10.4103/11102098.141713
5. Kumar S. Comparasion of intraoperative triamcinolone and Bevacizumab with conjuctival autograft alone in pterygium surgery. Indian Journal of Clinical Experimental Ophthalmology. 2020;6(1): 84-6.
DOI:https://doi.org/10.18231/j.ijceo.2020.019
6. Maurizi E, Schiroli D, Atkinson SD, Mairs L, Courtney DG, O'Hagan B et al. A novel role for CRIM1 in the corneal response to UV and pterygium development. Experimental Eye Research. 2019;179:75-92.
DOI:https://doi.org/10.1016/j.exer.2018.10.012. PMid:30365943.
7. Zhong H, Cha X, Wei T, Lin X, Li X, Li J, et al. Prevalence of and risk factors for pterygium in rural adult chinese populations of the Bai nationality in Dali: The Yunnan Minority Eye Study. 2012;53(10):6617-21.
DOI:https://doi.org/10.1167/iovs.11-8947. PMid:22956605.
8. Kiliç R, Kurt A, Tad M, Tasdemir S. Endocan overexpression in pterygium. Cornea. 2017;36(6):696-9.
DOI:https://doi.org/10.1097/ICO.0000000000001183. PMid:28410547.
9. Oellers P, Karp CL, Sheth A, Kao AA, Abdelaziz A, Matthews JL, et al. Prevalence, treatment, and outcomes of coexistent ocular surface squamous neoplasia and pterygium. Ophthalmology. 2013;120(3):445-50.
DOI:https://doi.org/10.1016/j.ophtha.2012.08.010. PMid:23107578 PMCid:PMC3562397.
10. Yin M, Li H, Zhang Y, Dai H, Luo F, Pan Z. Interferon Alpha-2b Eye Drops Prevent Recurrence of Pterygium After the Bare Sclera Technique: A Single-Center, Sequential, and Controlled Study. Cornea. 2019;38(10):1239.
DOI:https://doi.org/10.1097/ICO.0000000000001995. PMid:31299663. PMCid:PMC6750146.
11. Singh SK. Pterygium: Epidemiology prevention and treatment. Community Eye Health. 2017;30(99):S5.
12. Pyo EY, Mun GH, Yoon KC, Health. The prevalence and risk factors for pterygium in South Korea. Epidemiology. 2016;38:1- 7.
DOI:https://doi.org/10.4178/epih.e2016015PMid:27156345 PMCid:PMC5063818.
13. Chen T, Ding L, Shan G, Ke L, Ma J, Zhong Y, et al. Prevalence and racial differences in pterygium: a cross-sectional study in Han and Uygur adults in Xinjiang, China. Investigative Ophthalmology. 2015; 56(2):1109-17.
DOI: https://doi.org/10.1167/iovs.14-15994.
14. Rezvan F, Khabazkhoob M, Hooshmand E, Yekta A, Saatchi M, Hashemi H. Prevalence and risk factors of pterygium: A systematic review and meta-analysis. Survey of Ophthalmology. 2018;63(5):719-35.
DOI:https://doi.org/10.1016/j.survophthal.2018.03.001. PMid:29551597.
15. Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Current opinion in ophthalmology. 2007;18(4):308-13.
DOI:https://doi.org/10.1097/ICU.0b013e3281a7ecbb. PMid:17568207.
16. Zloto O, Rosen N, Leshno A, Rosner M, Eye A. Very long term success of pterygium surgery with conjunctival graft. Contact Lens. 2017;40(4):267-9.
DOI:https://doi.org/10.1016/j.clae.2017.05.004 PMid:28522251.
17. Hirst LW. Prospective study of primary pterygium surgery using pterygium extended removal followed by extended conjunctival transplantation. Ophthalmology. 2008;115(10):1663-72.
DOI:https://doi.org/10.1016/j.ophtha.2008.03.012. PMid:18555531.
18. Tan DT, Chee S-P, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Archives of Ophthalmology. 1997;115(10):1235- 40.
DOI:https://doi.org/10.1001/archopht.1997.01100160405001. PMid:9338666.
19. Rajiv Kumar Gupta SK, Marianus Deepak Lakra. Intraoperative triamcinolone versus bevacizumab as an adjunct to conjunctival autograft in primary pterygium surgery. International Journal of Contemporary Medical Research. 2017;4(2):557-60.
20. Ekibele C, Sarimiye T, Ogundipe A, Olaniyan S. 5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium. Eye Net. 2016;30(4):515-21.
DOI:https://doi.org/10.1038/eye.2016.29 PMid:26987589 PMCid:PMC5108553.
21. Kheirkhah A, Nazari R, Safi H, Ghassemi H, Behrouz M, Raju V. Effects of intraoperative steroid injection on the outcome of pterygium surgery. Eye Net. 2013;27(8):906.
DOI:https://doi.org/10.1038/eye.2013.142 PMid:23887766 PMCid:PMC3740317.
22. Mannis MJ. Kanski's Clinical Ophthalmology: A Systematic Approach. LWW; 2016.
23. Shimazaki J, Yang HY, Tsubota K, Retina I. Limbal autograft transplantation for recurrent and advanced pterygia. Ophthalmic Surgery, Lasers. 1996;27(11): 917-23.
24. Mednick Z, Boutin T, Einan-Lifshitz A, Sorkin N, Slomovic A. Simple limbal epithelial transplantation for recurrent pterygium: A case series. American Journal of Ophthalmology Case Reports. 2018;12:5-8
25. Dougherty PJ, Hardten DR, Lindstrom RLJC. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. 1996;15(5): 537-40.
DOI:https://doi.org/10.1097/00003226-199609000-00015.
26. Safi H, Kheirkhah A, Mahbod M, Molaei S, Hashemi H, Jabbarvand M. Correlations between histopathologic changes and clinical features in pterygia. Journal of Ophthalmic Vision Research. 2016;11(2): 153.
DOI:https://doi.org/10.4103/2008-322X.183917 PMid:27413494 PMCid:PMC4926561.
27. Cevc G, Blume G. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes®. Biochimica et Biophysica Acta -Biomembranes. 2003;1614(2):15664.
DOI:https://doi.org/10.1016/S00052736(03)00172-X.
28. Gupta R, Studies B. Outcome of autologous limbal conjunctival transplantation in terms of recurrence rate, as the main outcome measure and complications as the secondary outcome. International Journal of Medical. 2019; 3(5).
DOI:https://doi.org/10.32553/ijmbs.v3i5.242.
29. Demiryürek S, Saracaloglu A, Kimyon S, Mete A, Eronat O, Temiz E et al. Increased Expressions of ICAM-2 and ICAM-3 in Pterygium. Current eye research. 2019:1-6.
DOI:https://doi.org/10.1080/02713683.2019.1570527 PMid:30657707.
30. Shumway CL, Wade M. Anatomy, head and neck, eye conjunctiva. StatPearls [Internet]: StatPearls Publishing; 2018.
31. A, Pires RT, Tseng SC. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology. 2001;108(3):449-60.
DOI:https://doi.org/10.1016/S0161-6420(00)00567-4.
32. Figueiredo RS, Cohen EJ, Gomes JA, Rapuano CJ, Lailson PRJOS, Lasers, Retina I. Conjunctival autograft for pterygium surgery: How well does it prevent recurrence? 1997;28(2):99-104
33. Frucht-Pery J, Siganos CS, Ilsar M. Intraoperative application of topical mitomycin C for pterygium surgery. Ophthalmology. 1996;103(4):674-7.
DOI:https://doi.org/10.1016/S0161-6420(96)30635-0.
34. Lam DS, Wong AK, Fan DS, Chew S, Kwok PS, Tso MO. Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. Ophthalmology. 1998;105(5):901-5.
DOI:https://doi.org/10.1016/S0161-6420(98)95034-5
35. Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997;104(6):974-85.
DOI:https://doi.org/10.1016/S0161-6420(97)30197-3
36. Safi H, Kheirkhah A, Mahbod M, Molaei S, Hashemi H, Jabbarvand MJJoo et al. Correlations between histopathologic changes and clinical features in pterygia. 2016;11(2):153.
37. Prabhasawat P, Tesavibul N, Leelapatranura K, Phonjan T. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006;113(7):1102-9.
DOI:https://doi.org/10.1016/j.ophtha.2006.02.026 PMid:16730066.
38. Abdel Hamid M, El-Sersy TH. Role of Triamcinolone Acetate Injection in Recurrent Pterygium. Ain Shams Medical Journal. 2013;312(2076):1- 9.
DOI:https://doi.org/10.12816/0013831.
39. Athanasiadis Y, Tsatsos M, Sharma A, Hossain P, therapeutics. Subconjunctival triamcinolone acetonide in the management of ocular inflammatory disease. Journal of Ocular Pharmacology. 2013;29(6):516- 22.
DOI:https://doi.org/10.1089/jop.2012.0208
40. Kersey J, Broadway D. Corticosteroid-induced glaucoma: A review of the literature. Eye Net. 2006;20(4):407.
DOI:https://doi.org/10.1038/sj.eye.6701895 PMid:15877093.